Correct... You can see who the moles are today, trying to distract everyone from the most significant, approval related news from the call...
The eIND and CD10 data is being collected by the MHRA in anticipation of the CD12 interim results... EAMS is very much on the table.
Great post from other board- EAMS in U.K still very likely. EAMS is similar to FDA EAU - this is why they requested the additional data of the 60+ EIND if they see a bigger benefit than risk than they will most likely approve for EAMS Early Access medicines Scheme- they will be submitting data ASAP to U.K for consideration. With this possible U.K. funding I would presume